Pemetrexed and malignant pleural mesothelioma
نویسندگان
چکیده
منابع مشابه
Pemetrexed in malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM) is a disease with a poor prognosis, related in part to the aggressiveness of this disease, and in part due to the lack of drugs that have demonstrated tumor activity. Historically, antifolates such as methotrexate have been the most active drugs in the treatment of mesothelioma. Newer antifolates have recently demonstrated higher efficacy than older regimens...
متن کاملPemetrexed in malignant pleural mesothelioma.
PURPOSE This report describes the data and analysis leading to the approval of pemetrexed (LY 231514, MTA, Alimta, Eli Lilly and Co., Indianapolis, IN) by the U.S. Food and Drug Administration (FDA) of a New Drug Application for the treatment of malignant pleural mesothelioma (MPM). EXPERIMENTAL DESIGN The FDA review of the efficacy and safety of pemetrexed assessed in a randomized clinical t...
متن کاملPemetrexed in the treatment of malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a relatively uncommon tumor that is increasing in frequency in most areas of the world. For example, in the UK there has been a sharp increase in the number of cases since the late 1970s, a trend which is predicted to reach its peak by approximately 2015, when over 2000 cases per annum are likely to be diagnosed [1]. It is a tumor which is, in the vast ma...
متن کامل[Malignant pleural mesothelioma].
Overview Mesothelioma is a rare cancer that is estimated to occur in approximately 2500 people in the United States every year.1,2 These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on malignant pleural mesothelioma (MPM), which is the most common type; mesothelioma can also occur in other sites (e.g., peritoneum, pericardium, tunica vaginalis testis). The disease is di...
متن کاملMalignant pleural mesothelioma.
Malignant pleural mesotheliomas are tumors originating in the serosal lining of the pleural cavities. Although these are relatively rare tumors, an increasing number of cases are anticipated over the next decade. Patients with these tumors, which are almost invariably fatal, usually have an interval of less than two years between the onset of symptoms and death. There is a well established link...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2006
ISSN: 0923-7534
DOI: 10.1093/annonc/mdj962